RHHVF (Roche Holding AG) ROCE %: 23.21% (As of Dec. 2025)


RHHVF Roche Holding AG RHHVF
80 GF Score
Price $411.84
GF Value $331.52
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Roche Holding AG ROCE %?

Roche Holding AG RHHVF 80 ROCE % is 23.21% as of Dec. 2025. GuruFocus rates RHHVF with a GF Score™ of 80/100 and a GF Value™ of $331.52 (Modestly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Roche Holding AG's annualized ROCE % for the quarter that ended in Dec. 2025 was 23.21%.

Roche Holding AG  (OTCPK:RHHVF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Roche Holding AG ROCE % Related Terms

Roche Holding AG ROCE % Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG ROCE % Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.49 29.48 24.68 18.53 26.26

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.82 26.06 11.87 30.37 23.21
RHHVF
80GF Score
Roche Holding AG RHHVF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG ROCE % Calculation

Roche Holding AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=22987.828/( ( (114177.882 - 30308.434) + (126368.428 - 35137.407) )/ 2 )
=22987.828/( (83869.448+91231.021)/ 2 )
=22987.828/87550.2345
=26.26 %

Roche Holding AG's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=20175.68/( ( (116533.448 - 33915.396) + (126368.428 - 35137.407) )/ 2 )
=20175.68/( ( 82618.052 + 91231.021 )/ 2 )
=20175.68/86924.5365
=23.21 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 23.21% mean?
Roche Holding AG (RHHVF) has a ROCE % of 23.21% as of Dec. 2025.
Is Roche Holding AG's ROCE % too high?
Roche Holding AG's current ROCE % is 23.21%. The Drug Manufacturers industry median ROCE % is 7.00. Roche Holding AG's value of 23.21% is 231.8% above this industry median. Overall, Roche Holding AG has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's ROCE % compare to LLY and JNJ?
Roche Holding AG's ROCE % of 23.21% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Roche Holding AG's value of 23.21% is 231.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current ROCE % of 23.21% is 231.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current ROCE % is 23.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (RHHVF) is currently considered Modestly Overvalued. The stock's GF Value™ is $331.52, compared to a current price of $411.84 — trading 24.2% above its estimated fair value. The current ROCE % is 23.21% and 231.8% above the Drug Manufacturers industry median of 7.00. Roche Holding AG's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Roche Holding AG (RHHVF), the current ROCE % is 23.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (RHHVF) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of $411.84 is trading 24.2% above its estimated GF Value™ of $331.52. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for RHHVF:

  • ROCE %: 23.21%
  • GF Value™: $331.52 vs. price of $411.84 (24.2% above fair value)
  • GF Score™: 80/100 with 3 warning signs
  • Industry Position: 231.8% above the Drug Manufacturers median

No single metric tells the full story. See the RHHVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
80GF Score

Get the complete analysis for RHHVF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$411.84
Price
$331.52
GF Value